BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Average Rating of "Moderate Buy" from Analysts

Shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX - Get Free Report) have been given an average rating of "Moderate Buy" by the eighteen ratings firms that are currently covering the firm, Marketbeat reports. Four investment analysts have rated the stock with a hold recommendation, thirteen have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $137.86.

A number of research analysts recently commented on the stock. Wall Street Zen raised shares of BioNTech from a "sell" rating to a "hold" rating in a research report on Saturday, June 7th. Morgan Stanley dropped their target price on shares of BioNTech from $140.00 to $132.00 and set an "overweight" rating on the stock in a research report on Tuesday, May 6th. The Goldman Sachs Group assumed coverage on shares of BioNTech in a research report on Thursday, May 29th. They issued a "neutral" rating and a $110.00 target price on the stock. Citigroup reaffirmed a "buy" rating and issued a $140.00 target price (down from $145.00) on shares of BioNTech in a research report on Tuesday, May 6th. Finally, Truist Financial reaffirmed a "buy" rating and issued a $155.00 target price (up from $151.00) on shares of BioNTech in a research report on Tuesday, June 3rd.

BioNTech Stock Down 0.5%

Shares of NASDAQ BNTX traded down $0.57 during mid-day trading on Friday, reaching $104.40. The company had a trading volume of 894,938 shares, compared to its average volume of 949,716. The company has a current ratio of 10.18, a quick ratio of 10.02 and a debt-to-equity ratio of 0.01. The firm has a 50 day simple moving average of $101.79 and a two-hundred day simple moving average of $107.84. The stock has a market cap of $25.10 billion, a P/E ratio of -30.71 and a beta of 1.29. BioNTech has a 52-week low of $76.53 and a 52-week high of $131.49.

Institutional Trading of BioNTech

Several hedge funds and other institutional investors have recently made changes to their positions in BNTX. Banque Cantonale Vaudoise purchased a new stake in shares of BioNTech in the first quarter valued at about $36,000. Jones Financial Companies Lllp boosted its holdings in shares of BioNTech by 110.3% in the fourth quarter. Jones Financial Companies Lllp now owns 469 shares of the company's stock valued at $53,000 after acquiring an additional 246 shares in the last quarter. Banque Transatlantique SA purchased a new stake in shares of BioNTech in the first quarter valued at about $80,000. Quintet Private Bank Europe S.A. boosted its holdings in shares of BioNTech by 823.5% in the fourth quarter. Quintet Private Bank Europe S.A. now owns 785 shares of the company's stock valued at $88,000 after acquiring an additional 700 shares in the last quarter. Finally, Allianz SE purchased a new stake in shares of BioNTech in the fourth quarter valued at about $90,000. Hedge funds and other institutional investors own 15.52% of the company's stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.